Effects of late administration of pentoxifylline and tocotrienols in an image-guided rat model of localized heart irradiation
- PMID: 23894340
- PMCID: PMC3718790
- DOI: 10.1371/journal.pone.0068762
Effects of late administration of pentoxifylline and tocotrienols in an image-guided rat model of localized heart irradiation
Abstract
Radiation-induced heart disease (RIHD) is a long-term side effect of radiotherapy of intrathoracic, chest wall and breast tumors when radiation fields encompass all or part of the heart. Previous studies have shown that pentoxifylline (PTX) in combination with α-tocopherol reduced manifestations of RIHD in rat models of local heart irradiation. The relative contribution of PTX and α-tocopherol to these beneficial effects are not known. This study examined the effects of PTX alone or in combination with tocotrienols, forms of vitamin E with potential potent radiation mitigation properties. Rats received localized X-irradiation of the heart with an image-guided irradiation technique. At 3 months after irradiation rats received oral treatment with vehicle, PTX, or PTX in combination with a tocotrienol-enriched formulation. At 6 months after irradiation, PTX-treated rats showed arrhythmia in 5 out of 14 animals. PTX alone or in combination with tocotrienols did not alter cardiac radiation fibrosis, left ventricular protein expression of the endothelial markers von Willebrand factor and neuregulin-1, or phosphorylation of the signal mediators Akt, Erk1/2, or PKCα. On the other hand, tocotrienols reduced cardiac numbers of mast cells and macrophages, but enhanced the expression of tissue factor. While this new rat model of localized heart irradiation does not support the use of PTX alone, the effects of tocotrienols on chronic manifestations of RIHD deserve further investigation.
Conflict of interest statement
Figures
References
-
- Early Breast Cancer Trialists Collaborative Group (2000) Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Lancet 355: 1757-1770. doi:10.1016/S0140-6736(00)02263-7. PubMed: 10832826. - DOI - PubMed
-
- Galper SL, Yu JB, Mauch PM, Strasser JF, Silver B et al. (2011) Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation. Blood 117: 412-418. doi:10.1182/blood-2010-06-291328. PubMed: 20858859. - DOI - PubMed
-
- Chera BS, Rodriguez C, Morris CG, Louis D, Yeung D et al. (2009) Dosimetric comparison of three different involved nodal irradiation techniques for stage II Hodgkin’s lymphoma patients: conventional radiotherapy, intensity-modulated radiotherapy, and three-dimensional proton radiotherapy. Int J Radiat Oncol Biol Phys 75: 1173-1180. doi:10.1016/j.ijrobp.2008.12.048. PubMed: 19386423. - DOI - PubMed
-
- Kole TP, Aghayere O, Kwah J, Yorke ED, Goodman KA (2012) Comparison of Heart and Coronary Artery Doses Associated with Intensity-Modulated Radiotherapy Versus Three-Dimensional Conformal Radiotherapy for Distal Esophageal Cancer. Int J Radiat Oncol Biol Phys 83: 1580-1586. doi:10.1016/j.ijrobp.2011.10.053. PubMed: 22284687. - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
